PMV Pharmaceuticals/$PMVP
1D1W1MYTD1Y5YMAX
About PMV Pharmaceuticals
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
- Ticker
- $PMVP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 54
- Headquarters
- Princeton, United States
- Website
- www.pmvpharma.com
PMVP Metrics
BasicAdvanced
$65M
-
-$1.41
1.35
-
Price and volume
Market cap
$65M
Beta
1.35
52-week high
$1.88
52-week low
$1.02
Average daily volume
268K
Financial strength
Current ratio
7.703
Quick ratio
7.516
Total debt to equity
0.303
Profitability
EBITDA (TTM)
-79.543
Effective tax rate (TTM)
-0.03%
Management effectiveness
Return on assets (TTM)
-42.39%
Return on equity (TTM)
-70.93%
Valuation
Price to book
0.91
Price to tangible book (TTM)
0.91
Price to free cash flow (TTM)
-0.911
Free cash flow yield (TTM)
-109.76%
Free cash flow per share (TTM)
-1.339
Growth
Earnings per share change (TTM)
-9.42%
3-year earnings per share growth (CAGR)
-4.47%
What the Analysts think about PMVP
Analyst ratings (Buy, Hold, Sell) for PMV Pharmaceuticals stock.
PMVP Financial Performance
Revenues and expenses
PMVP Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.